| Literature DB >> 28243308 |
Yan Dong1, Jiangquan Liao2, Kuiwu Yao1, Wenrui Jiang1, Jie Wang1.
Abstract
Atrial fibrillation (AF) is the most common cardiac arrhythmia, which is related to many cardiac and cerebral vascular diseases, especially stroke. It can therefore increase cardiovascular mortality and all-cause death. The current treatments of AF remain to be western drugs and radiofrequency ablation which are limited by the tolerance of patients, adverse side effects, and high recurrence rate, especially for the elderly. On the contrary, traditional Chinese medicine (TCM) with long history of use involves various treatment methods, including Chinese herbal medicines (CHMs) or bioactive ingredients, Chinese patent medicines, acupuncture, Qigong, and Tai Chi Chuan. With more and more researches reported, the active roles of TCM in AF management have been discovered. Then it is likely that TCM would be effective preventive means and valuable additional remedy for AF. The potential mechanisms further found by numerous experimental studies showed the distinct characteristics of TCM. Some CHMs or bioactive ingredients are atrial-selective, while others are multichannel and multifunctional. Therefore, in this review we summarized the treatment strategies reported in TCM, with the purpose of providing novel ideas and directions for AF management.Entities:
Year: 2017 PMID: 28243308 PMCID: PMC5294366 DOI: 10.1155/2017/1381732
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Application of single CHMs or bioactive ingredients in AF.
| Original plant | Medicinal part | Bioactive ingredient | Methods of study | Result | Mechanism | Effect on the four principles of AF |
|---|---|---|---|---|---|---|
|
| Root | Berberine | Cellular study (rat and human atrial cells) | Vasodilation, positive ionotropic and negative chronotropic actions | Inhibition of Ito by binding to open state channels or shifting of the steady-state inactivation curve of Ito [ | Rate and rhythm control management of primary disease and risk factors |
| Root | Berberine | Animal study (rabbit) | Suppressing AF | Inhibiting Ito [ | Rhythm control | |
| Root | Berberine | Cellular study (guinea pig cardiac myocytes) | Multichannel ion blocker | Inhibiting KATP [ | / | |
|
| ||||||
|
| Flower [ | Sesquiterpene lactone fraction [ | Animal study (rat) | Anti-inflammatory and analgesic effects [ | Stabilization of lysosomal membranes and an antiproliferative effect [ | Management of risk factors |
| Flower | Acacetin | Animal study (dog) | Suppressing AF | Inhibition of Kach, Kur, and Ito as an atrial-selective agent, prolonging APD and ERP without prolonging the corrected QT interval [ | Rhythm control | |
|
| ||||||
|
| Flower heads | Catechin and epicatechin | Cellular study | Antiplatelet aggregation | Inhibiting the biosynthesis of thromboxane A2 [ | Antithrombotic therapy |
| Fruit | Extract (containing flavonoid and procyanidin) | Cellular study (guinea pig ventricular myocytes) | Antiventricular arrhythmia | Prolonging the APD through blocking the delayed (IK) and inward (IK1) rectifier potassium currents [ | / | |
| Fruit | LI 132 (Faros® 300, CRA) [ | Animal study (Wistar rats heart) [ | Positive ionotropic action, improving exercise capacity and decreasing mortality in heart failure patients [ | Increasing Ca (2+)-concentration intracellularly [ | Management of primary disease | |
| Fruit | Epicatechin, hyperoside, and fluid extract | Cellular study (DPPH and ABTS techniques) | Antioxidant activity [ | / | Management of risk factors | |
|
| ||||||
|
| Tuber | Rotundium | Clinical research (AF patients) | Suppressing AF | Prolonging the ERP of atrial and atrioventricular node [ | Rhythm control |
| Tuber | D-Corydaline, d-glaucine, protopine, and l-tetrahydrocolumbamine | Animal study (rat) | Antiplatelet aggregation [ | / | Antithrombotic therapy | |
| Tuber | Pseudocoptisine | Cellular study (RAW 264.7 murine macrophage cells) | Anti-inflammatory | Reducing levels of iNOS, COX-2, necrosis factor-alpha (TNF-alpha), and IL-6 through the inhibition of nuclear factor kappa B (NF-kappaB) activation via the suppression of ERK and p38 phosphorylation [ | Management of risk factors | |
|
| ||||||
|
| Aerial parts | Primary and refined extracts | Cellular and organ studies (rabbit, rat, and guinea pig) | Decreasing the blood pressure, heart rate and increasing coronary blood flow and treating ventricular or sinus tachyarrhythmias [ | Inhibiting the inward calcium (ICaL) and potassium (IKr) channels, lengthening Q-T, P-Q intervals and the activation time constant of I (f) in pacemaker cells [ | Rate control and management of risk factors |
| Aerial parts | / | Clinical research | Fibrinolysis effect and antiplatelet aggregation | Decreasing blood viscosity, fibrinogen volume and increasing the deformability of Rbc [ | Antithrombotic therapy | |
| Aerial parts | Rutin and derivatives of hydroxycinnamic acid | Cellular study | Antioxidant activity [ | / | Management of risk factors | |
Application of Traditional Chinese patent medicines in AF.
| Chinese patent medicine | Component | Methods of study | Result | Mechanism | Effect on the four principles of AF |
|---|---|---|---|---|---|
| Wenxin granule |
| Clinical research (AF patients) [ | Shortening conversion time, decreasing the required dosage of amiodarone and avoiding the adverse reaction [ | Inhibition of INa selectivity in atrium [ | Rhythm control |
| Animal study (dog) | Lowering AF inducibility after the ganglionic plexi (GP) ablation | Suppressing atrial substrate remodeling without increasing the levels of ANP, TNF- | Management of risk factors and rhythm control | ||
|
| |||||
| Shen Song Yang Xin capsule |
| Clinical research (paroxysmal AF patients) | Paroxysmal AF [ | / | Rhythm control |
| Cellular study (rabbit pulmonary vein cardiomyocytes) | Prolonging APD | Depressing the ICa-L, Ito, and IK1 [ | Rhythm control | ||
| Animal study (rat) [ | Treating premature ventricular contractions and ventricular arrhythmias [ | Blocking INa, ICaL, Ito, and IK1 [ | / | ||
|
| |||||
| Shenmai injection | Ginseng saponins, radix ophiopogonis saponins, radix ophiopogonis flavonoids and traces of ginseng polysaccharides, and radix ophiopogonis polysaccharide | Clinical research | Converting AF into sinus rhythm | Prolonging ERP [ | Rhythm control |
Application of nondrug methods in AF.
| Name | Methods of study | Result | Effect on the four principles of AF |
|---|---|---|---|
| Acupuncture | Clinical research (paroxysmal AF and atrial flutter patients) | Increasing the rate of cardioversion [ | Rhythm control |
| Clinical research (paroxysmal and persistent AF patients) | Decreasing recurrences of persistent AF after cardioversion [ | Rhythm control | |
|
| |||
| Qigong (including Baduanjin) | Clinical research | Improving physical rehabilitation of AF [ | / |
| Clinical research | Reversing adverse left ventricular remodeling [ | Management of risk factors | |
| Clinical research | Promoting multisystem or organ functions, increasing immunity, making bodies relax, and improving mood and confidence of elderly populations [ | Management risk factors | |
| Clinical research | Lowering blood pressure [ | Management of primary disease | |
| Clinical research | Modulating the blood lipid metabolism [ | Management of primary disease | |
| Clinical research | Antioxidant activity and reducing oxidative stress [ | Management of risk factors | |
|
| |||
| Tai Chi Chuan | Clinical research | Improvement of cardiorespiratory function [ | Management of risk factors |
| Clinical research | Reducing CVD risk factors [ | Management of risk factors | |
| A meta-analysis | Lowering blood triglyceride level [ | Management of primary disease | |
| A literature search | Improvement in mental health [ | Management of risk factors | |